bryan johnson tirzepatide Microdosing Tirzepatide & Ozempic (GLP-1)

They tracked body mass index (BMI) changes during the first year after treatment began and compared them with later health outcomes through June 2025

Pharmaceutical stability of semaglutide in various reconstitution conditions

Generics face possible delayed brand patent expirations Brian Hart, vice president, Communications, Association for Accessible Medicines, a group that works to ensure accessibility of generics and biosimilars, tells PharmaCircle that while brand manufacturers products are showing tremendous clinical benefit across a wide array of conditions, there may be an underlying reason for exploring these products

Drop volume and intensity by 20 to 30% for the first two weeks at a new dose, then build back up as you adapt

New England Journal of Medicine 381, 841851